Cue Biopharma, Inc. 8-K

What Happened

• On April 30, 2026, Cue Biopharma (CUE) announced a License Agreement with Ascendant Health Sciences Ltd. giving Cue exclusive, sublicensable rights to develop, manufacture and commercialize Ascendant-221 (anti‑IgE) and related products outside mainland China, Hong Kong, Macau and Taiwan. Consideration includes a $15.0 million upfront payment, up to $676.5 million in potential milestone payments and tiered royalties (high single‑digit to low double‑digit) on net sales.
• In connection with the license, Cue agreed to issue Ascendant pre‑funded warrants to buy up to 551,724 shares (exercise $0.001) as partial consideration and may issue additional shares or pre‑funded warrants to give Ascendant up to 7.5% ownership upon achievement of specified Top‑Up milestones (subject to a $15.0 million value threshold and stockholder approval where required).
• Also on April 30, 2026, Cue agreed to a private placement expected to close around May 4, 2026 to sell pre‑funded warrants (up to 2,727,272) and warrants (up to 1,363,636) at $11.00 each, expected to raise about $30 million gross (≈$28M net). The investors include Cue’s newly appointed President & CEO, Dr. Shao‑Lee Lin.
• On April 27–30, 2026 the Board adopted a 2026 Inducement Stock Incentive Plan (3,000,000 shares) and appointed Dr. Shao‑Lee Lin as President & CEO effective April 30, 2026. Her employment package includes a $660,000 annual base salary, target bonus up to 55% of salary, an initial option for 655,074 shares and a fully vested RSU for 327,537 shares, plus possible Top‑Up equity tied to milestones. Interim CEO Lucinda Warren resigned effective April 30 and has a separation arrangement with severance and equity vesting provisions.

Key Details

• Upfront payment: $15.0 million; potential milestone payments: up to $676.5 million (includes $5.0M manufacturing transfer, $6.5M data transfer, up to $205.0M development/regulatory incl. a Phase 2 milestone, and up to $460.0M commercial milestones).
• Royalties: tiered royalties on net sales ranging from high single‑digit to low double‑digit percentages; royalty term runs product‑by‑product/country until later of 10 years from first sale, patent expiry or regulatory exclusivity.
• Equity/consideration: Ascendant to receive pre‑funded warrants for up to 551,724 shares now; potential Top‑Up to reach ≥7.5% ownership (value floor $15.0M) subject to Nasdaq stockholder approvals and lock‑up/standstill terms.
• Financing: Private placement expected to generate ≈$30M gross (~$28M net) via pre‑funded warrants and warrants (exercise mechanics and transfer restrictions apply); registration and stockholder approvals required.

Why It Matters

• The license gives Cue global development and commercialization rights for Ascendant‑221 in most markets outside Greater China, providing a new clinical asset that could expand Cue’s pipeline and future revenue potential if development and approvals succeed.
• The deal includes substantial milestone and royalty obligations and involves equity consideration and warrant issuances that will dilute current shareholders and require stockholder approvals; there are also lock‑up and standstill limits on Ascendant’s share sales and voting.
• The near‑term financing (expected ≈$28M net) and the appointment of an experienced biotech executive as CEO signal a push to accelerate development and commercialization plans, but many outcomes depend on clinical milestones, registration efforts and satisfaction of closing conditions described in the filing.